Group 1 - The article promotes a subscription service called "The Dividend Dogcatcher" which provides insights and portfolios for dividend stocks [1] - It highlights a live video segment called "Underdog Daily Dividend Show" that features potential investment candidates [1] - The article encourages audience engagement by inviting comments on favorite or least favorite stock tickers for future reports [1]

Energy Transfer (NYSE: ET) is a toll taker, operating one of the largest midstream businesses in North America. And it has been very rewarding for income investors of late. That comes from both the distribution yield, which is a lofty 7%, and distribution growth. Here's what you need to know before you buy it. Energy Transfer has a good streak going Energy Transfer's distribution was increased every quarter in 2025. Every quarter in 2024. Every quarter in 2023. And every quarter in 2022. That's the kind ...

IBM just got hit with one of its worst single-day drops in years. Shares fell over 13.2% on Feb. 23, 2026, closing at $223.35. The culprit? Anthropicannounced its Claude Code tool could automate much of the tedious, expensive work involved in COBOL modernization — a key IBM (IBM) business. That panic-driven sell-off pushed IBM stock down more than 24% year to date. For growth investors, that's a problem. But for dividend hunters, the drop may have opened a door worth walking through. The question isn't w ...

Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4% dividend yield. For reference, the average pharma stock has a yield of just 1.7%. There's a reason to buy Pfizer beyond the yield. Pfizer gets you most of the way to 10% If you buy Pfizer and collect that 6.4% dividend yield, you are roughly two-thirds of the way toward the 10% return that most investors expec ...

AbbVie (NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currently high yield and strong cash flow, AbbVie could provide dividend lovers with reliable income for years to come. AbbVie's yield is attractive The S&P 500 index has a paltry yield of 1.1% today. The average pharmaceutical company, using iShares U.S. Pharmaceuticals ETF a ...

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo Nordisk and Eli Lilly build early leads in this fast-growing drug niche. With Pfizer facing patent expirations ahead -- and now this GLP-1 setback -- Wall Street remains downbeat on the stock. But that's a potential opportunity for long-term investors. Where to invest $1,000 right now? Our analyst team just reveale ...

Core Viewpoint - Conagra Brands offers a substantial 7% dividend yield, attracting dividend investors, but faces significant risks that may affect its attractiveness as an investment [3][5][6] Investment Considerations Buy Conagra Brands? - The primary reason to consider buying Conagra is its high dividend yield of 7%, appealing to dividend-focused investors [3] - As a consumer staples company, Conagra is viewed as a safe investment during market volatility, providing essential products at reasonable prices [3] Sell Conagra Brands? - The dividend payout ratio is concerning, especially since the company reported a loss, with the ratio previously exceeding 100%, indicating potential risks to the dividend's safety [5][6] - In the fiscal second quarter of 2026, Conagra reported a loss of $1.39 per share, primarily due to non-cash goodwill and brand impairment charges, which, if excluded, would have resulted in earnings of $0.45 per share, covering the $0.35 quarterly dividend [6] Hold Conagra Brands? - Investors who have benefited from the stock's price increase in 2026 may consider taking profits and reallocating to higher-quality competitors like Coca-Cola, despite the potential loss of yield [9] - Conagra's organic sales declined by 3% in the fiscal second quarter of 2026, contrasting with Coca-Cola's 5% increase, highlighting challenges in maintaining sales amid changing consumer preferences [10]

Core Viewpoint - Energy Transfer offers a high dividend yield of nearly 7.2%, significantly higher than the S&P 500's yield of 1.2%, making it an attractive investment for income generation [1][4]. Dividend and Investment Requirements - Energy Transfer pays quarterly distributions of $0.335 per unit, totaling $1.34 annually, with a 3% increase in distribution over the past year [4][6]. - To generate $500 monthly, an investment of approximately $84,000 is required at the current price of $18.75 per unit, needing 4,478 units to achieve an annual income of $6,000 [4][5]. Comparison with Other Investments - In contrast, generating the same $500 monthly income from an S&P 500 index fund would require an investment of nearly $522,000, highlighting the efficiency of Energy Transfer's higher yield [5]. Financial Stability and Growth - Energy Transfer maintains a stable cash flow, with 90% derived from predictable fee-based sources, and pays out only about 50% of its cash flow in dividends, allowing for reinvestment in expansion projects [6]. - The company plans to spend over $5 billion on growth capital this year, with projects expected to enter commercial service through the end of the decade, supporting annual distribution increases of 3% to 5% [7]. Investment Considerations - Despite its attractive yield, Energy Transfer was not included in a recent list of the 10 best stocks for investors by The Motley Fool Stock Advisor, suggesting a need for careful consideration before investing [8].

Core Insights - The Schwab US Dividend Equity ETF (SCHD) is currently the most popular dividend ETF in the market, but there are alternative options that may offer higher growth potential, particularly in a strong technology sector [1] - The Vanguard Dividend Appreciation ETF (VIG) is highlighted as one of the alternative options alongside SCHD [1] Summary by Category - **Popular Dividend ETFs** - SCHD is recognized as the leading dividend ETF in popularity [1] - **Alternative Options** - Other dividend ETFs are suggested for consideration, especially during periods of strong technology performance [1] - VIG is specifically mentioned as a notable alternative to SCHD [1]

Core Viewpoint - Nucor Corporation is facing significant challenges with negative free cash flow and declining net income, raising concerns about the sustainability of its dividend despite a strong balance sheet and a long history of dividend payments [1][2]. Financial Performance - Nucor generated negative free cash flow of $188 million in 2025, marking the first time in its history that it failed to produce positive free cash flow [1]. - The company paid out $512 million in dividends during 2025, consuming 25.1% of net income, a sharp increase from 5.3% in 2022 [1]. - Net income fell 75% to $2.04 billion in 2025, down from $8.08 billion in 2022, with operating cash flow dropping 68% from its peak [1][2]. Dividend Analysis - The latest quarterly dividend of $0.56 per share represents a modest 1.82% increase from the previous quarter, with a full-year dividend of $2.21 per share, up just 1.84% from 2024 [1]. - The current dividend yield is 1.15%, significantly below the S&P 500 average, making it less attractive for income-focused investors [1][2]. Cash Flow and Capital Expenditures - Operating cash flow for fiscal 2025 was $3.23 billion, while capital expenditures were $3.42 billion, leading to negative free cash flow [1]. - The company has a strong balance sheet with $2.70 billion in cash and a $2.25 billion undrawn credit facility, providing a cushion to support dividend payments [1][2]. Market Valuation - Nucor's stock is priced at 26 times trailing earnings and 17 times forward earnings, indicating that the market is betting on future earnings growth rather than current dividend income [2]. - The stock has appreciated 46.62% over the past year, driven by expectations of a cyclical recovery in the steel industry [2]. Economic Context - U.S. GDP growth accelerated to 4.4% in Q3 2025, which could support industrial demand and improve Nucor's cash generation in 2026 [2]. - Management is optimistic about increased earnings in Q1 2026, driven by higher volumes and prices, which could restore positive cash flow [2]. Insider Activity - Recent insider transactions show a concerning trend, with 15 disposals compared to only 2 acquisitions, indicating a lack of confidence from management [1]. - Notable sales include CEO Leon Topalian and CFO Stephen Laxton disposing of shares, which raises questions about their outlook on the company's performance [1].